Hepatitis C in cirrhosis patients: Difference between revisions
Varun Kumar (talk | contribs) (Created page with "{{Hepatitis C}} {{CMG}}; {{AOEIC}} {{VK}} ==Recommendations for Treatment of Persons with Compensated and Decompensated Cirrhosis: AASLD Practice Guidelines 2009<ref name="pm...") |
m (Changes made per Mahshid's request) |
||
| Line 20: | Line 20: | ||
[[Category:Hepatitis|C]] | [[Category:Hepatitis|C]] | ||
[[Category:Gastroenterology]] | [[Category:Gastroenterology]] | ||
[[Category:Disease]] | [[Category:Disease]] | ||
Latest revision as of 17:56, 18 September 2017
|
Hepatitis C |
|
Diagnosis |
|
Treatment |
|
Hepatitis C in cirrhosis patients On the Web |
|
American Roentgen Ray Society Images of Hepatitis C in cirrhosis patients |
|
Risk calculators and risk factors for Hepatitis C in cirrhosis patients |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-In-Chief: Varun Kumar, M.B.B.S. [2]
Recommendations for Treatment of Persons with Compensated and Decompensated Cirrhosis: AASLD Practice Guidelines 2009[1]
| “ |
1.Patients with HCV-related compensated cirrhosis (CTP class A), can be treated with the standard regimen of pegylated interferon and ribavirin but will require close monitoring for adverse events (Class I, Level A). 2. Patients with HCV-related decompensated cirrhosis should be referred for consideration of liver transplantation (Class I, Level B). 3. Interferon-based therapy may be initiated at a lower dose in patients with decompensated cirrhosis (CTP class B and C), as long as treatment is administered by experienced clinicians with vigilant monitoring for adverse events preferably in patients who have already been accepted as candidates for liver transplantation (Class IIb, Level B). 4. Growth factors can be used for treatment-associated anemia and leukopenia to improve quality of life and may limit the need for antiviral dose reductions in patients with decompensated cirrhosis (Class IIb, Level C). |
” |
References
- ↑ Swan T, Curry J (2009). "Comment on the updated AASLD practice guidelines for the diagnosis, management, and treatment of hepatitis C: treating active drug users". Hepatology (Baltimore, Md.). 50 (1): 323–4, author reply 324–5. doi:10.1002/hep.23077. PMID 19554546. Retrieved 2012-02-21. Unknown parameter
|month=ignored (help)